Swedish solar developer Alight will build and operate for Axel Johnson AB two more solar farms, bringing to over 90 GWh the combined annual production contracted by the family-owned industrial group.
Under one of the deals announced on Thursday, Axel Johnson food retail and wholesale subsidiary Axfood AB (STO:AXFO) has signed a power purchase agreement (PPA) with Alight for a 40-MW solar park that will be producing 40 GWh per year, enough to cover about 15% of the firm's electricity consumption.
NextEra Energy Partners LP (NYSE:NEP) said on Friday it has agreed to buy a 50% stake in a renewable energy portfolio totalling 2,520 MW and also entered into a convertible equity portfolio financing for USD 824 million (EUR 709m).
The growth-oriented limited partnership formed by NextEra Energy Inc (NYSE:NEE) is buying the portfolio interest from a subsidiary of NextEra Energy Resources LLC for a total consideration of USD 849 million plus NEP's share of the portfolio's total tax equity financings, estimated at USD 866 million at the time of closing.
El Gobierno ha herido de gravedad la figura de los planes de pensiones individuales, el vehículo de inversión más utilizado en España para ahorrar de cara a la jubilación. Hasta el año pasado, los trabajadores y autónomos podían aportar hasta 8.000 euros anualmente a este instrumento. Todo lo que aportasen se lo descontaban de la base imponible del Impuesto de la Renta (IRPF). Quien tuviera una base imponible de 60.000 y metiera 8.000 euros a su plan, solo tributaba por 52.000 euros.
Rollos de papel higiénico, zapatillas deportivas, juguetes e incluso disfraces infantiles para la fiesta de Halloween son estos días objeto de deseo en Estados Unidos por culpa de la crisis de desabastecimiento que recorre el mundo y que ha gripado la actividad en la meca del consumo.
Algo no está bien en la globalización cuando el comprador de un coche debe esperar nueve meses para recibir su vehículo; cuando los barcos cargados de contenedores hacen cola durante más de una semana en los puertos de Róterdam, Amberes o Los Ángeles. Algo pasa cuando en la industria juguetera hay empresas que no saben si tendrán a tiempo sus productos para la lucrativa campaña navideña. Cuando las plantas de automóviles paran porque no tienen semiconductores y las obras se demoran ante la escasez de madera, aluminio o acero.
Pocas misiones espaciales científicas han sido tan esperadas como la del telescopio espacial James Webb (Webb). Como el próximo gran observatorio espacial científico después del Hubble, Webb se ha diseñado para resolver preguntas sin respuesta sobre el universo e investigar más allá de nuestros orígenes: desde la formación de estrellas y planetas, hasta el nacimiento de las primeras galaxias en el universo primigenio.
Historically, one of the biggest hurdles facing pharmaceutical research and development has been the laboratory itself. While laboratory instruments have seen considerable advancement over the years, scientists spend more time on the logistics of setting up and running laboratory experiments than they do designing experiments and interpreting results. This is a significant complication for start-up and fast-growing companies that are continually challenged to scale their operations while keeping a sharp eye on their budgets.
In the years to come, industrial research and development (R&D) must continue to change and adapt in order to successfully offer new products, processes, services, solutions and business models to global markets and international customers.
Since by definition R&D is oriented towards the future, this study is intended to provide R&D managers with support for strategic and operational future orientation. “Industrial R&D is subject to continuous change, which is accompanied by discontinuities, technological trends and changes in the market environment.“
COVID-19 re-shaped the life sciences industry. In the race to find a vaccine, widespread collaboration became the norm, with pharmaceutical companies, not-for-profits and academic institutions sharing data and research. Trust in big pharma increased, with 49 percent of people saying they view the pharmaceutical industry more positively than before the pandemic.1